Hosted on MSN38m
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)
Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
Sage stock price target cut to $12 by H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...
Arvinas price target lowered to $81 from $87 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...
HC Wainwright Issues Pessimistic Forecast for XFOR Earnings
Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for X4 Pharmaceuticals in a research note issued on Friday, February 7th. HC Wainwright analyst S. Ramakanth now forecasts ...
FY2029 Earnings Estimate for ZVRA Issued By Roth Capital
Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Sunday, February 9th. Roth Capital analyst J.